The latest price target for Skye Bioscience (NASDAQ:SKYE) was reported by Scotiabank on September 30, 2024. The analyst firm set a price target for $20.00 expecting SKYE to rise to within 12 months (a possible 640.74% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Skye Bioscience (NASDAQ:SKYE) was provided by Scotiabank, and Skye Bioscience initiated their sector outperform rating.

There is no last upgrade for Skye Bioscience

There is no last downgrade for Skye Bioscience.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Skye Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Skye Bioscience was filed on September 30, 2024 so you should expect the next rating to be made available sometime around September 30, 2025.

While ratings are subjective and will change, the latest Skye Bioscience (SKYE) rating was a initiated with a price target of $0.00 to $20.00. The current price Skye Bioscience (SKYE) is trading at is $2.70, which is within the analyst’s predicted range.